

|     |                                                                                                                                                                                                   |                                |         |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|---------|
| R&D | Pfizer Lithuania - 2024                                                                                                                                                                           |                                |         |
|     | AGGREGATE DISCLOSURE /<br>APIBENDRINTAS ATSKAITOMUMAS                                                                                                                                             |                                |         |
|     | Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1<br>/<br>Perkeltos vertės, susijusios su moksliniais tyrimais ir plėtra, kaip apibrėžta 3.04 str ir 1 Priede | TOTAL AMOUNT /<br>SUMA IŠ VISO | 11533,1 |
|     |                                                                                                                                                                                                   |                                |         |